Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Immunocore Holdings's Enterprise Value is $1,191.1 Mil.
Immunocore Holdings's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 was $-35.0 Mil. Therefore, Immunocore Holdings's EV-to-OCF for today is -34.07.
The historical rank and industry rank for Immunocore Holdings's EV-to-OCF or its related term are showing as below:
IMCR'
s EV-to-OCF Range Over the Past 10 Years
Min: -230.36 Med: -7.47 Max: 1437.82
Current: -34.07
During the past 8 years, the highest EV-to-OCF of Immunocore Holdings was 1437.82. The lowest was -230.36. And the median was -7.47.
IMCR's EV-to-OCF is ranked better than 88.75% of 1405
companies
in the Biotechnology industry
Industry Median: -3.38
vs IMCR: -34.07
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Immunocore Holdings's PE Ratio (TTM) for today is calculated as:
Immunocore Holdings's share price for today is $31.825.
Immunocore Holdings's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.370.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Immunocore Holdings EV-to-OCF Related Terms
Immunocore Holdings EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Immunocore Holdings's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Immunocore Holdings's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Immunocore Holdings EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Immunocore Holdings's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Immunocore Holdings's EV-to-OCF falls into.
Immunocore Holdings's current Enterprise Value is $1,191.1 Mil.
Immunocore Holdings's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-35.0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Immunocore Holdings (IMCR) has a EV-to-OCF of -34.07 as of Sep. 15, 2026. According to the industry distribution chart, Immunocore Holdings ranks #158 out of 1405 companies in the Biotechnology industry, placing it in the top 11.2%.
Is Immunocore Holdings' EV-to-OCF too high?
Immunocore Holdings' current EV-to-OCF is -34.07. Based on the distribution chart, Immunocore Holdings ranks #158 out of 1405 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Immunocore Holdings has a GF Score™ of 80/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Immunocore Holdings' EV-to-OCF compare to TSHA and KARD?
According to the Biotechnology industry distribution chart, Immunocore Holdings ranks #158 out of 1405 companies for EV-to-OCF. This places Immunocore Holdings in the top 11% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. Immunocore Holdings's current EV-to-OCF is -34.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Immunocore Holdings stock overvalued right now?
Based on GuruFocus' analysis, Immunocore Holdings (IMCR) is currently considered Possible Value Trap. The stock's GF Value™ is $45.35, compared to a current price of $31.83 — trading 29.8% below its estimated fair value. The current EV-to-OCF is -34.07. Immunocore Holdings' overall GF Score™ is 80/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Immunocore Holdings (IMCR), the current EV-to-OCF is -34.07 as of Sep. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Immunocore Holdings (IMCR) Overvalued in 2026?
Based on GuruFocus' analysis, Immunocore Holdings stock appears to be undervalued.
The current stock price of $31.83 is trading 29.8% below its estimated GF Value™ of $45.35.
GuruFocus considers Immunocore Holdings to be Possible Value Trap.
Key valuation signals for IMCR:
EV-to-OCF: -34.07
GF Value™: $45.35 vs. price of $31.83 (29.8% below fair value)
No single metric tells the full story. See the IMCR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.
80GF Score
Get the complete analysis for IMCR
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IMCR has been successfully added to your 
